Literature DB >> 14688828

Significance of p53, Bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer.

Mansour Al-Moundhri1, V Nirmala, K Al-Mawaly, S Ganguly, I Burney, A Rizvi, C Grant.   

Abstract

Racial disparity in the presentation of breast cancer and the outcome of its treatment is well established. However, the causes remain unexplained. The scarcity of reports about the prognostic significance of p53, bcl-2, and HER-2/neu in Arab females with breast cancer has been the impetus to this study. We evaluated the prognostic significance of altered expression of p53, bcl-2, HER-2/neu in Omani Arab females with non-metastatic breast cancer with correlation to other established prognostic factors. We have retrospectively analyzed the immunohistochemical expression of p53, HER-2/neu and bcl-2 in paraffin embedded blocks of 72 females diagnosed with invasive breast cancer between 1992 and 2002. The expression of the above proteins was correlated with other prognostic factors and univariate and multivariate analysis was carried out for all prognostic factors. Overexpression of p53 significantly correlated with younger age (<40), pre-menopausal status, poor differentiation with inverse correlation with bcl-2 expression. Expression of bcl-2 immunopostivity significantly correlated to low histological grade and positive estrogen and progesterone receptor status. On univariate and multivariate p53 overexpression and lack of bcl-2 immunostaining resulted in worse survival outcome, but not Her-2/neu overexpression. Expression patterns of p53 and bcl-2 are independent predictors of survival in Omani Arab population which may help to stratify these patients into different risk groups.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688828     DOI: 10.1007/BF02893382

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  35 in total

1.  Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.

Authors:  M Ferrero-Poüs; K Hacène; C Bouchet; V Le Doussal; M Tubiana-Hulin; F Spyratos
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

2.  p53 expression is of independent predictive value in lymph node-negative breast carcinoma.

Authors:  M Fresno; R Molina; M J Pérez del Río; S Alvarez; J M Díaz-Iglesias; I García; A Herrero
Journal:  Eur J Cancer       Date:  1997-07       Impact factor: 9.162

3.  Current status of breast cancer in Hong Kong.

Authors:  L W Chow; A C Ting; K L Cheung; G K Au; T T Alagaratnam
Journal:  Chin Med J (Engl)       Date:  1997-06       Impact factor: 2.628

4.  [Breast cancer in Tunisia: clinical and epidemiological study].

Authors:  M Maalej; H Frikha; S Ben Salem; J Daoud; N Bouaouina; M Ben Abdallah; K Ben Romdhane
Journal:  Bull Cancer       Date:  1999-03       Impact factor: 1.276

5.  Down-regulation of bcl-2 by p53 in breast cancer cells.

Authors:  S Haldar; M Negrini; M Monne; S Sabbioni; C M Croce
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

6.  Unique features of breast cancer in Taiwan.

Authors:  S H Cheng; M H Tsou; M C Liu; J J Jian; J C Cheng; S Y Leu; C Y Hsieh; A T Huang
Journal:  Breast Cancer Res Treat       Date:  2000-10       Impact factor: 4.872

7.  Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.

Authors:  A Bánkfalvi; K Tory; M Kemper; D Breukelmann; C Cubick; C Poremba; L Füzesi; R J Lellè; W Böcker
Journal:  Pathol Res Pract       Date:  2000       Impact factor: 3.250

8.  Expression of cellular oncogenes in human malignancies.

Authors:  D J Slamon; J B deKernion; I M Verma; M J Cline
Journal:  Science       Date:  1984-04-20       Impact factor: 47.728

9.  Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.

Authors:  G P Rosanelli; P Steindorfer; G H Wirnsberger; M Klimpfinger; M Ratschek; P Puerstner; H Auner; A Berhold
Journal:  Anticancer Res       Date:  1995 Mar-Apr       Impact factor: 2.480

10.  erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

Authors:  A D Thor; D A Berry; D R Budman; H B Muss; T Kute; I C Henderson; M Barcos; C Cirrincione; S Edgerton; C Allred; L Norton; E T Liu
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

View more
  5 in total

1.  Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients.

Authors:  Gabriela A Balogh; Daniel Mailo; Hector Nardi; Maria Marta Corte; Esteban Vincent; Elena Barutta; Guillermo Lizarraga; Pablo Lizarraga; Hector Montero; Roberto Gentili
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

2.  High prevalence of HER-2/neu overexpression in female breast cancer among an Iraqi population exposed to depleted uranium.

Authors:  Esraa A Al-Dujaily; Asad A Al-Janabi; Tomasz Pierscionek; Akeel A Yasseen
Journal:  J Carcinog       Date:  2008

Review 3.  Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.

Authors:  Grace M Callagy; Mark J Webber; Paul D P Pharoah; Carlos Caldas
Journal:  BMC Cancer       Date:  2008-05-29       Impact factor: 4.430

4.  Systematic review of breast cancer biology in developing countries (part 1): Africa, the middle East, eastern europe, Mexico, the Caribbean and South america.

Authors:  Riyaz Bhikoo; Sanket Srinivasa; Tzu-Chieh Yu; David Moss; Andrew G Hill
Journal:  Cancers (Basel)       Date:  2011-05-13       Impact factor: 6.639

5.  Correlation of Hormone Receptor and Human Epidermal Growth Factor Receptor-2/neu Expression in Breast Cancer with Various Clinicopathologic Factors.

Authors:  Cherry Bansal; Aarti Sharma; Mukta Pujani; Meenu Pujani; Kiran Lata Sharma; A N Srivastava; U S Singh
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.